Partnerships Will Provide the Virta Treatment as a Fully-Covered Healthcare Benefit to Employees of Tippecanoe County Government and the City of Lafayette, Indiana
SAN FRANCISCO, California:Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, today announced new commercial partnerships with Tippecanoe County Government, Indiana and the City of Lafayette, Indiana. The two alliances expand Virta Health’s presence in the region and provide access to the Virta Treatment as a fully-covered healthcare benefit to employees of Tippecanoe County Government and the City of Lafayette Government.
“The Virta Treatment has been revolutionary for our employees living with type 2 diabetes,” said Tony Roswarski, mayor of the City of Lafayette. “Virta’s ability to reverse, not manage, type 2 diabetes aligns with the innovative approach we take to improve the health of our employees. Furthermore, we anticipate the economic savings to be substantial and a huge win for the city.”
Sources indicate there are more than 10,000 individuals living with T2D in Tippecanoe County alone, costing the county an estimated $56 million annually. By combining a highly-individualized nutritional approach, medical supervision, and innovations in technology and artificial intelligence, the Virta Treatment helps people eliminate medications safely and sustainably while simultaneously lowering blood sugar and restoring metabolic health. This approach saves an estimated $9,600 per individual in the first 24 months, thereby drastically reducing T2D-induced economic burden while also significantly improving patient health.
“We are making massive strides in improving the health of an entire region,” said Sami Inkinen, Virta Health co-founder and CEO. “Thanks to our long-standing partnership with Purdue University, the largest employer in the county, and our clinical trial work in conjunction with Indiana University Health Arnett, we have the opportunity to drastically reduce the regional economic burden while helping thousands of people live a diabetes-free life.”
Peer-reviewed results from Virta’s ongoing clinical trial demonstrated that the Virta Treatment led to T2D reversal in 60% of patients at one year, with 94 percent of insulin users reducing or stopping usage altogether. Additional just-released cardiovascular outcomes for T2D patients showed that the Virta Treatment improved 22 of 26 markers of cardiovascular disease risk, including blood pressure, obesity, and inflammation. A group receiving usual care saw no significant improvements in any of the same 26 markers.
In addition, Virta Health recently raised a $45 million Series B funding round, bringing the company’s total equity funding to $75 million to date. The investment enables Virta Health to expand its partnership programs with employers, health plans and governments, advance its technology tools for both patients and clinicians, and continue to scale the Virta Treatment to the millions of individuals currently suffering from T2D and other reversible, chronic diseases.“
Seeing my results on the Virta Treatment, including dramatic improvements in weight, A1c, and medication use, and discussing how the economic savings could be multiplied across the organization really resonated with my employer," said Shirley Mennen, Virta patient and Human Resource Director in charge of Benefits at Tippecanoe County Government. “I am extremely proud to say that Tippecanoe County is now offering the Virta Treatment to all our covered employees and dependents and am looking forward to seeing many other lives improved because of this awesome benefit."
For more information about Virta Health and the science behind reversing type 2 diabetes and other chronic metabolic diseases, visit www.virtahealth.com.
Virta Health delivers the first clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery. At one year, 60% of patients in our clinical trial achieved diabetes reversal, 94% of insulin users reduced or eliminated usage altogether and 83% of patients remained active in the trial. Results extended beyond diabetes reversal, with sustained improvements in blood pressure, inflammation, cardiovascular markers, insulin resistance and weight loss. For enterprises, Virta saves nearly $10,000 per patient in medical expenses over the first 24 months while tying treatment fees to successful outcomes. The Virta Treatment, delivered through a technology-enabled online clinic, will help millions of people get their lives back while making type 2 diabetes a thing of the past. To learn more, visit www.virtahealth.com or follow us on Twitter @virtahealth.
.jpg)
